| Net sales for the quarter increased by 21.74 per cent to Rs 300.19 crore from Rs 246.58 crore in the corresponding quarter of the previous year. |
| The drug maker today announced a dividend of Rs 13 for every equity share of Rs 10 each besides an additional special dividend of Rs 11 per share. The total dividend payout will be Rs 260 crore. |
| According to the company, an improvement in operating margins, working capital management and the sale of properties has resulted in a favourable cash position, which is around Rs 700 crore (before the dividend payout). |
| The company has lined up new product launches led by its patented anti-diabetic drug rosiglitazone in 2005. It will launch hypertension drugs in 2006. |
| "We will soon be entering into growing market segments like cardiovascular, diabetes, and central nervous system. We are exploring in-licensing opportunities in the gynaecology, gastroenterology and nutritional segments," S Kalyansundaram, managing director, GlaxoSmithKline Pharmaceuticals, said in a media conference. |
| For the year ended December 31, the company posted a net profit of Rs 333.09 crore against Rs 172.23 crore in the previous year, up 93.3 per cent. |
| Profit after tax and before exceptional items was up by 16 per cent at Rs 266 crore. Sales for the year was Rs 1479.59 against Rs 1191.69 crore. |
| The net profit includes exceptional items to the tune of Rs 67.04 crore comprising sale of land at Worli in Mumbai, employee separation cost on account of closure of its Bangalore and Mysore factories. |
Top Section
Explore Business Standard